Human Chorionic Gonadotropin — NCD 125 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 125 governing hCG testing coverage, effective March 7, 2026. Here's what billing teams need to know before submitting claims.

CMS hCG coverage policy under NCD 125 Medicare sets clear frequency and clinical limits on human chorionic gonadotropin testing. The policy covers hCG for monitoring germ cell neoplasms and certain pregnancy complications — but caps diagnostic testing at once per month. The policy does not list specific CPT or HCPCS codes in the current version, so your team needs to confirm applicable codes through the quarterly Covered Code Lists linked in the policy document.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Human Chorionic Gonadotropin
Policy Code	NCD 125
Change Type	Modified
Effective Date	2026-03-07
Impact Level	Medium
Specialties Affected	Oncology, Obstetrics/Gynecology, Laboratory, Urology, Neurosurgery
Key Action	Audit hCG claim frequency — diagnostic testing is limited to once per month under this coverage policy

---

CMS Human Chorionic Gonadotropin Coverage Criteria and Medical Necessity Requirements 2026

NCD 125 is the National Coverage Determination that governs Medicare coverage of hCG testing. It covers two distinct clinical uses, and the medical necessity standard differs between them.

The first covered use is monitoring and diagnosis of germ cell neoplasms. These are tumors that can arise in the ovary, testis, mediastinum, retroperitoneum, and central nervous system. If your facility or lab bills hCG testing in these oncology contexts, coverage applies — but frequency matters.

The second covered use is monitoring pregnant patients with vaginal bleeding, hypertension, and/or suspected fetal loss. These are qualifying clinical circumstances. A claim without documentation tying the test to one of these conditions is a medical necessity problem waiting to happen.

Here's where the policy gets strict: CMS will not consider it reasonable and necessary to perform hCG testing more than once per month for diagnostic purposes. That's a hard ceiling. Monitoring-based testing — where you're tracking treatment progress rather than establishing a diagnosis — can be done more frequently, but the documentation must support a monitoring rationale, not a diagnostic one.

This distinction between diagnostic and monitoring use is the core billing risk in this policy. Your medical records need to clearly show which purpose each test serves. Vague or generic orders like "hCG testing" without clinical context are the fastest path to a claim denial.

Prior authorization is not explicitly required under NCD 125 as written. But that doesn't mean you're safe from audit. CMS uses frequency data to flag outlier claims, and labs or providers billing diagnostic hCG more than once per month are going to draw scrutiny.

Reimbursement for hCG testing falls under the Clinical Laboratory Fee Schedule. The effective date of March 7, 2026 applies to claims processed on or after that date, so if you have claims in flight from earlier in Q1, confirm whether they were adjudicated under the prior version of the policy.

---

CMS Human Chorionic Gonadotropin Exclusions and Non-Covered Indications

There's one explicit exclusion in NCD 125, and it's worth stating plainly: qualitative hCG assays are not appropriate for medically managing patients with known or suspected germ cell neoplasms.

This matters because qualitative hCG tests only return a positive or negative result. They don't give you a measurable level. For oncology patients — where you need to track tumor marker trends over time — that's clinically insufficient. CMS is telling you that billing a qualitative assay in this context is not medically necessary by definition.

Quantitative testing is the appropriate method for germ cell neoplasm monitoring. If your lab or ordering provider defaults to qualitative testing in these cases, the claim won't hold up. Fix the order set before this becomes a denial pattern.

The real issue here is that labs sometimes run qualitative tests reflexively — it's faster, it's cheaper — and then bill without considering how the result maps to the clinical indication. NCD 125 closes that door specifically for oncology monitoring.

---

Coverage Indications at a Glance

---

CMS hCG Billing Guidelines and Action Items 2026

These are direct steps for your billing team based on what NCD 125 actually says.

Copy Action Items

If you're uncertain how your current hCG billing volume maps to these criteria, loop in your compliance officer before the effective date. Frequency outliers are exactly what post-payment audits target.

---

CPT, HCPCS, and ICD-10 Codes for Human Chorionic Gonadotropin Under NCD 125

Covered CPT and HCPCS Codes

The current version of NCD 125 (Policy Key: 125-v1, effective March 7, 2026) does not list specific CPT or HCPCS codes directly in the policy document. CMS publishes applicable codes through quarterly Covered Code Lists, which are linked within the policy.

Your team must reference the most current quarterly Covered Code List to confirm which codes are covered under this policy. Do not rely on codes from prior quarters without verifying against the current list.

Code	Type	Description Copy
See quarterly Covered Code List	CPT/HCPCS	CMS publishes applicable hCG codes on a quarterly basis — not directly in NCD 125

Key ICD-10-CM Diagnosis Codes

NCD 125 does not enumerate ICD-10 codes directly. However, based on the covered clinical indications in the policy, your documentation should support one of the following clinical scenarios:

• Germ cell neoplasm of the ovary, testis, mediastinum, retroperitoneum, or CNS
• Pregnancy with vaginal bleeding
• Pregnancy with hypertension
• Suspected fetal loss

Work with your coding team to confirm the ICD-10-CM codes that match these documented indications. Pairing the correct diagnosis code to the hCG test is what makes a medical necessity argument stick on audit.

---